Study of an investigational drug with chemotherapy for lung or breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial is testing a new drug called IMM2510 in combination with chemotherapy as a first treatment for people with non-small cell lung cancer or triple-negative breast cancer. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have one of the following: non-small cell lung cancer (with certain gene types) or triple-negative breast cancer.
- You have not received any prior treatment for advanced cancer, except for certain earlier-stage treatments that ended more than 12 months ago.
- You are able to perform daily activities with minimal help (ECOG score 0 or 1), and you have measurable tumors.
- You can provide a tumor tissue sample (from a previous biopsy or a new one) for testing.
- You agree to use effective contraception during the study and for 6 months after the last dose.
- You do not have certain other medical conditions, including autoimmune diseases, uncontrolled infections, or recent use of other cancer treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new drug combination (RC148 plus chemotherapy) with a standard immunotherapy (tislelizumab) plus chemotherapy for people with a common type of lung cancer. It tests whether the new combination works better as a first treatment for advanced cancer.
This trial tests a new drug (RC148) plus chemotherapy against another drug (Tislelizumab) plus chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or can't be removed. It's for those who haven't had treatment for advanced disease yet.
This study tests a combination of two immune-based drugs, IMM2510 and IMM27M, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of cancer.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.